Mechanisms of carbapenems resistance in acinetobacter and progress of treatment.
- Author:
Wei ZHANG
1
;
Kai-Zhong LIU
Author Information
1. Intensive Care Unit, Zhejiang Cancer Hospital, Hangzhou 310022, China.
- Publication Type:Journal Article
- MeSH:
Acinetobacter;
drug effects;
enzymology;
Acinetobacter Infections;
drug therapy;
Anti-Bacterial Agents;
pharmacology;
therapeutic use;
Bacterial Proteins;
metabolism;
Carbapenems;
pharmacology;
therapeutic use;
Drug Resistance, Bacterial;
Microbial Sensitivity Tests;
beta-Lactamases;
metabolism
- From:
Journal of Zhejiang University. Medical sciences
2010;39(5):542-547
- CountryChina
- Language:Chinese
-
Abstract:
Acinetobacter has been the major pathogen of nosocomial infection. With the wide use of carbapenems, the emergence of multi-resistant isolates especially those resistant to carbapenem, brings a great problem to clinical treatment. The production of inactive enzymes is the main mechanism for antibiotic resistance, particularly the production of carbapenemases mediated by chromosome or plasmid. Combinations of β-lactam antibiotics and sulbactam may show synergism or partial synergism for acinetobacter isolates.
